Mary Jones Introduces MF Grape And Cola Flavors With Latest Cannabis Beverage Launch

Jones Soda Co. (OTCQB: JSDA) (CSE: JSDA) announced two new flavors of its Mary Jones cannabis-infused beverage brand. The new additions include 10mg and 100mg THC-infused MF Grape and Cola flavors.

Jones Soda Co. (OTCQB:JSDA) (CSE:JSDA) announced two new flavors of its Mary Jones cannabis-infused beverage brand. The new additions include 10mg and 100mg THC-infused MF Grape and Cola flavors. Both flavors will be available at California dispensaries starting in early June 2023 with additional recreational cannabis states to come this year.

The 10mg MF Grape and Cola cannabis sodas come in single-serving 12 oz glass bottles. The 100mg sodas are packaged in 16 oz resealable, child-resistant, multi-serve cans.

“Mary Jones dipped into the cupboards of the mainline brand once again due to demand for its MF Grape and Cola flavors among cannabis consumers, transferring Jones’ most popular favorites to the THC community,” stated Brooks Jorgensen, president at KSS. “Cola was strategically driven. It’s an iconic flavor profile. With MF Grape, Jones fans have demanded its return, so it was brought back in both mainline Jones and Mary Jones.”

Mark Murray, president and CEO of Jones Soda, stated: “Our team has been getting calls and emails from dispensaries and cannabis consumers in other legal states about how they can get Mary Jones locally. They know the Jones brand and want Mary Jones products. There’s a special romance with these two classic Jones flavors among consumers. MF Grape and Cola are great additions to Mary Jones.”

Photo by Michael Veronneau on Unsplash

Related News

Jones Soda Co. Adds Sparkle To Q1 Revenue, Strong Growth In Cannabis Segment

Mary Jones Cannabis Sodas & Edibles Expanding To Michigan And Nevada

Jones Soda 2022 Revenue Grows 29% To $19.1M, What About Adjusted EBITDA?
 

 

Total
0
Shares
Related Posts
Read More

Ocuphire Provides Corporate Update And Reiterates Previous Guidance On Clinical Programs; PDUFA Date Of September 28, 2023 Set For Nyxol; Preliminary Cash Balance As Of March 31, 2023 Of $39M Is Expected To Fund Operations Into 2025

PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval   Oral APX3330 End of Phase

OCUP